Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...2728293031323334353637...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Enrollment change, Trial termination:  A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) -  Aug 6, 2025   
    P2,  N=7, Terminated, 
    N=80 --> 7 | Unknown status --> Terminated; This study was voluntarily terminated after investigator assessment, with no safety concerns identified related to the trial intervention or procedures. The primary reason for termination was difficulty in patient recruitment.
  • ||||||||||  cyclosporine ophthalmic emulsion / Generic mfg., NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
    Journal:  Early Adoption and Utilization of Perfluorohexyloctane for Dry Eye Disease in the United States. (Pubmed Central) -  Aug 6, 2025   
    To characterize early adopters of perfluorohexyloctane (PFHO) and 90-day refill rates after the first prescription, overall and compared to a cohort initiating cyclosporine ophthalmic emulsion 0.05% (CsA)...High DED medication use among PFHO patients in the 12-month period prior to treatment initiation suggests that prior medication may not have resolved their DED symptoms. The higher 90-day refill rate for PFHO versus CsA indicates a higher degree of patient satisfaction with this new, first-in-class treatment for DED.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  A Study of SHR-1210 (clinicaltrials.gov) -  Aug 5, 2025   
    P2,  N=194, Completed, 
    The higher 90-day refill rate for PFHO versus CsA indicates a higher degree of patient satisfaction with this new, first-in-class treatment for DED. Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Jul 2025 | Trial primary completion date: Dec 2022 --> Jul 2025
  • ||||||||||  Itari (linperlisib) / Shanghai YingLi Pharma
    Trial completion date, Trial primary completion date:  Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (clinicaltrials.gov) -  Aug 5, 2025   
    P2,  N=41, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Jul 2025 | Trial primary completion date: Dec 2022 --> Jul 2025 Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Oct 2025
  • ||||||||||  HRS-5965 / Jiangsu Hengrui Pharma
    Enrollment open:  A Trial of HRS-5965 Capsule in Primary IgA Nephropathy (clinicaltrials.gov) -  Aug 5, 2025   
    P3,  N=378, Recruiting, 
    Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Jun 2025 --> Oct 2025 Not yet recruiting --> Recruiting
  • ||||||||||  ribupatide injection (HRS9531 injection) / Kailera Therapeutics
    Enrollment open:  Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin (clinicaltrials.gov) -  Aug 5, 2025   
    P3,  N=300, Recruiting, 
    Statistical analyses were performed using GraphPad Prism version 7.0, employing Student's t-tests for comparisons between groups. Not yet recruiting --> Recruiting
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Journal:  Effects of Esketamine Combined With Remimazolam Tosylate on Hemodynamics During Cardiovascular Anesthesia. (Pubmed Central) -  Aug 1, 2025   
    The combination of esketamine and remimazolam tosylate offers hemodynamic stability, enhances cerebral oxygen metabolism, improves cognitive function, and reduces myocardial injury in patients undergoing heart valve replacement surgery. This approach might provide significant benefits in cardiovascular anesthesia.
  • ||||||||||  cisplatin / Generic mfg., paclitaxel / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group
    Retrospective data, Journal:  Analysis of camrelizumab in neoadjuvant chemotherapy for esophageal cancer: A retrospective cohort study. (Pubmed Central) -  Aug 1, 2025   
    Neoadjuvant camrelizumab combined with paclitaxel and cisplatin may notably enhance pCR rates in locally advanced ESCC, with a manageable safety profile. The present findings suggest potential clinical benefit, but confirmation through prospective, randomized trials is essential to validate the regimen's efficacy and long-term outcomes.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion, Enrollment change, Trial completion date:  Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC (clinicaltrials.gov) -  Jul 31, 2025   
    P2,  N=81, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | N=178 --> 81 | Trial completion date: Dec 2024 --> Jun 2025
  • ||||||||||  M9466 / EMD Serono
    Enrollment change, Trial completion date, Trial primary completion date:  M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) (clinicaltrials.gov) -  Jul 31, 2025   
    P1,  N=141, Recruiting, 
    Recruiting --> Completed | N=178 --> 81 | Trial completion date: Dec 2024 --> Jun 2025 N=96 --> 141 | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027
  • ||||||||||  remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
    Trial completion date, Trial primary completion date:  Impact of Remimazolam on Prognosis After Bladder Cancer Surgery (clinicaltrials.gov) -  Jul 30, 2025   
    P4,  N=1128, Recruiting, 
    This research offers new strategies for precision treatment of locally advanced HER2-positive breast cancer. Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
  • ||||||||||  Review, Journal:  Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance. (Pubmed Central) -  Jul 30, 2025   
    Investigational compounds, including crenolanib, bezuclastinib, famitinib, motesanib, midostaurin, IDRX-42, and olverembatinib, are under development to address resistant or wild-type GISTs...Future strategies include precision medicine approaches such as ctDNA-guided therapy, rational drug combinations, and novel drug delivery systems to optimize bioavailability and reduce toxicity. Ongoing research will be crucial for refining treatment sequencing and expanding therapeutic options, especially for rare GIST subtypes.
  • ||||||||||  Enrollment change, Trial completion date, Trial primary completion date:  Renaissance: Reverse Triple Negative Immune Resistant Breast Cancer (clinicaltrials.gov) -  Jul 28, 2025   
    P2,  N=70, Recruiting, 
    National Natural Science Foundation of China and Natural Science Foundation of Jiangsu Province. N=30 --> 70 | Trial completion date: Mar 2023 --> Mar 2027 | Trial primary completion date: Dec 2022 --> Dec 2026
  • ||||||||||  SHR-A1909 / Jiangsu Hengrui Pharma
    Trial completion, Enrollment change:  A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) -  Jul 28, 2025   
    P1,  N=12, Completed, 
    N=30 --> 70 | Trial completion date: Mar 2023 --> Mar 2027 | Trial primary completion date: Dec 2022 --> Dec 2026 Recruiting --> Completed | N=100 --> 12
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  A Trial of SHR1258 in Patients With Biliary Tract Cancer (clinicaltrials.gov) -  Jul 25, 2025   
    P2,  N=0, Withdrawn, 
    Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027 N=70 --> 0 | Trial completion date: Aug 2022 --> Jun 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2022 --> Jun 2025